Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors

Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR. We have recently identified cyclin-dependent kinase 5 (Cdk5) as novel alternat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Weitensteiner, Sabine B., Liebl, Johanna, Krystof, Vladimir, Havlíček, Libor, Gucký, Tomáš, Strnad, Miroslav, Fürst, Robert, Vollmar, Angelika M., Zahler, Stefan
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545992/
https://ncbi.nlm.nih.gov/pubmed/23336010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0054607
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars